Forty quarters equals 400
This article was originally published in Scrip
Scrip's most recent analysis of long-term trends in pharma innovation, Reaping in due season? R&D trends and novel drug launches, shows that the number of truly original cancer drugs launched per year has more than doubled in a decade – from around four per year in 2000-2003 to nearly 10 per year in 2010-12. But in CNS that number has halved in the period – from six to just over three.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.